It’s hard to even talk about US FDA’s legal efforts without discussing the First Amendment in the wake of court cases such as US v. Caronia that have broadened firm’s right to “truthful and non-misleading” speech, says the agency's Chief Counsel Rebecca Wood.
Wood highlighted the First Amendment, as well as preemption and product safety issues, as three FDA legal office priorities during...